Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Status:
Completed
Trial end date:
1998-06-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the
treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS).
II. Determine the side-effects and benefits associated with DAP.